RVMD/Form 4: COO Margaret Horn sells shares under 10b5-1 plan

Rhea-AI Filing Summary

Margaret A. Horn, Chief Operating Officer and Director of Revolution Medicines, reported a sale of 4,775 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. After the transaction she beneficially owns 145,900 shares, which the filing states includes 70,500 restricted stock units (RSUs). The sale was executed under a Rule 10b5-1 instruction letter adopted May 31, 2023, to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Horn on 09/18/2025.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating the sale was pre-planned and follows an established instruction letter
• Reporting shows transparency by disclosing the amount sold, price, remaining beneficial ownership, and that RSUs are included in holdings

Negative

• Reduction in beneficial ownership by 4,775 shares following the reported sale
• 70,500 RSUs are outstanding, which may result in future withholding or sales upon vesting

Insights

Securities Analyst

TL;DR: A routine insider sale under a 10b5-1 plan to cover tax withholding; not an unusual governance event.

The Form 4 documents a disposition of 4,775 shares at $45.8249 executed pursuant to a Rule 10b5-1 plan tied to RSU vesting. Such sales commonly reflect withholding or diversification needs rather than discretionary trading. The remaining beneficial ownership of 145,900 shares, including 70,500 RSUs, keeps the reporting person materially invested in the company while addressing tax obligations.

Corporate Governance Expert

TL;DR: Use of an established 10b5-1 program indicates pre-planned, compliant handling of insider tax liabilities.

The filing clearly states the transaction was made under a 10b5-1 instruction adopted May 31, 2023, to satisfy tax withholding on RSU vesting. That transparency and advance planning reduce concerns about opportunistic insider selling. The Form 4 was properly executed by an attorney-in-fact and filed by one reporting person, reflecting standard procedural compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Horn Margaret A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		S(1)		4,775	D	$45.8249	145,900(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 70,500 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Margaret Horn	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Margaret Horn report on Form 4 for Revolution Medicines (RVMD/RVMDW)?

The Form 4 reports a sale of 4,775 shares on 09/16/2025 at $45.8249 per share and shows 145,900 shares beneficially owned after the transaction.

Why was the sale executed under a Rule 10b5-1 plan?

The filing states the sale was made pursuant to a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023.

How many restricted stock units (RSUs) does the filing disclose?

The filing discloses that the beneficial ownership total of 145,900 shares includes 70,500 RSUs.

Who signed the Form 4 filing and when?

The Form 4 is signed by Jack Anders, as Attorney-in-fact for Margaret Horn on 09/18/2025.

Was this Form 4 filed by one reporting person or jointly?

The form indicates it was filed by one reporting person.